儿童慢性移植物抗宿主病的代谢组学鉴定:α-酮戊二酸升高
本研究对222例儿童造血干细胞移植受者进行纵向血浆代谢组学分析,发现α-酮戊二酸在慢性GVHD诊断前(D100)及发病时持续升高,且不受严重程度、青春期状态或既往急性GVHD影响。晚期急性GVHD在D100具有独特的代谢模式,与慢性GVHD不同。α-酮戊二酸是关联慢性GVHD最显著的单一代谢物,这些代谢模式可能改善慢性GVHD的亚分类。
要点
- α-酮戊二酸在儿童cGVHD诊断前(D100)及发病时持续升高。
- 晚期急性GVHD在D100具有独特代谢模式,与cGVHD不同。
- α-酮戊二酸是关联cGVHD最显著的单一代谢物。
核心结论
- 血浆α-酮戊二酸在儿童cGVHD诊断前及发病时持续升高,是关联cGVHD最显著的单一代谢物。
- 晚期急性GVHD在D100具有独特的代谢模式,与cGVHD不同。
- 这些代谢模式可能改善cGVHD的亚分类,但需未来验证。
研究设计与样本
- 纵向评估儿童HSCT受者cGVHD和晚期aGVHD的代谢组学模式。
- 对ABLE/PBMTC1202研究中222例可评估儿童受者进行血浆代谢物定量分析。
- 在D100对随后发生cGVHD或晚期aGVHD的受者进行风险分配分析,并与非cGVHD对照比较。
- 诊断时分析使用固定和混合多元回归,比较cGVHD发病时与时间匹配的非cGVHD对照。
主要发现
- α-酮戊二酸在cGVHD诊断前(D100)及发病时持续升高,不受cGVHD严重程度、青春期状态或既往aGVHD影响。
- 晚期aGVHD在D100具有与cGVHD不同的独特代谢组学模式。
- 在D100风险分配和诊断时分析中,α-酮戊二酸均为关联cGVHD最显著的单一代谢物。
- 观察到与肺部、新发和进展型cGVHD临床表现相关的其他代谢组学关联模式。
关键数值与推荐
- 代谢组学生物标志物需满足全部3项选择标准:P ≤ .05;效应比≥1.3或≤0.75;ROC AUC ≥0.60。
临床怎么用
- α-酮戊二酸可能作为儿童cGVHD的候选生物标志物,用于风险分配和诊断辅助。
- 代谢组学模式可能有助于区分cGVHD与晚期aGVHD,并改善cGVHD亚分类。
- 这些探索性结果需未来验证后方可用于临床决策。
局限性
- 结果为探索性,需未来验证。
- 样本来自单一研究ABLE/PBMTC1202的222例可评估儿童受者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic graft-versus-host disease (cGVHD) is the most common cause for non-relapse mortality postallogeneic hematopoietic stem cell transplant (HSCT). However, there are no well-defined biomarkers for cGVHD or late acute GVHD (aGVHD). This study is a longitudinal evaluation of metabolomic patterns of cGVHD and late aGVHD in pediatric HSCT recipients. A quantitative analysis of plasma metabolites was performed on 222 evaluable pediatric subjects from the ABLE/PBMTC1202 study. We performed a risk-assignment analysis at day + 100 (D100) on subjects who later developed either cGVHD or late aGVHD after day 114 to non-cGVHD controls. A second analysis at diagnosis used fixed and mixed multiple regression to compare cGVHD at onset to time-matched non-cGVHD controls. A metabolomic biomarker was considered biologically relevant only if it met all 3 selection criteria: (1) P ≤ .05; (2) effect ratio of ≥1.3 or ≤0.75; and (3) receiver operator characteristic AUC ≥0.60. We found a consistent elevation in plasma α-ketoglutaric acid before (D100) and at the onset of cGVHD, not impacted by cGVHD severity, pubertal status, or previous aGVHD. In addition, late aGVHD had a unique metabolomic pattern at D100 compared with cGVHD. Additional metabolomic correlation patterns were seen with the clinical presentation of pulmonary, de novo, and progressive cGVHD. α-ketoglutaric acid emerged as the single most significant metabolite associated with cGVHD, both in the D100 risk-assignment and later diagnostic onset analysis. These distinctive metabolic patterns may lead to improved subclassification of cGVHD. Future validation of these exploratory results is needed. This trial was registered at www.clinicaltrials.gov as #NCT02067832.
引用
- Subburaj D, Ng B, Kariminia A, et al. Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease. Blood. 2022. PMID: 34534280. doi:10.1182/blood.2021013244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。